Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors.

Broekhuizen, L.N., van Wijk, D.F., Vink, H., Stalmach, A. , Crozier, A., Hutten, B.A., Kastelein, J.J.P., Hugenholtz, P.G., Koenig, W. and Stroes, E.S.G. (2011) Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors. British Journal of Nutrition, pp. 1-7. (doi: 10.1017/S0007114511002431)

Abstract

Inflammation is a hallmark of the metabolic syndrome, which also contributes to a pro-atherogenic state. NF-κB activation, a critical step in regulating inflammatory reactions, can be inhibited by polyphenol (PF) extracts, at least in vitro. In the present study, we set out to study whether a PF-rich extract could attenuate the chronic inflammatory state and/or an acute immune response in vivo in subjects with clustered metabolic risk factors. A commercially available, PF-rich extract (500 mg daily) or placebo was administered for 4 weeks to thirty-four subjects with two or more metabolic risk factors using a randomised, double-blind, cross-over design. During the final study visit, an acute inflammatory challenge (lipopolysaccharide (LPS) 1 ng/kg body weight) was administered to a random subgroup of subjects (PF-rich extract (n 12) and placebo (n 12)). The PF-rich extract modestly reduced the inflammatory chemokines monocyte chemoattractant protein 1 (MCP-1) and macrophage migration inhibitory factor (MIF) (MCP-1 - 6·5 % (PF, median 116 (interquartile range 97-136) pg/ml v. placebo, median 124 (interquartile range 105-153) pg/ml; P < 0·05); MIF - 10·8 % (PF, median 2512 (interquartile range 1898-3972) pg/ml v. placebo, median 2814·5 (interquartile range 2296-3852) pg/ml; P < 0·05); however, other measured markers of inflammation and cardiometabolic disease, such as C-reactive protein, IL-6, HDL-cholesterol, adiponectin and oxidised LDL, remained unaffected. Following the LPS challenge, we found a statistically significant 48% reduction of MCP-1 production in the PF-rich extract group (n 12) v. placebo (n 12) over 6 h (PF 766 (sd 155) v. placebo 1466 (sd 989) ng/ml; P < 0·05, area under the curve). In conclusion, short-term oral administration of the PF-rich extract caused a modest anti-inflammatory effect in subjects with clustered metabolic risk factors. Further dose-ranging studies are needed to evaluate whether and to what extent PF-rich extracts can be used to reduce the pro-inflammatory state in subjects with metabolic diseases at increased cardiovascular risk.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Stalmach, Dr Angelique and Crozier, Professor Alan
• Authors: Broekhuizen, L.N., van Wijk, D.F., Vink, H., Stalmach, A., Crozier, A., Hutten, B.A., Kastelein, J.J.P., Hugenholtz, P.G., Koenig, W., and Stroes, E.S.G.
• College/School: College of Medical Veterinary and Life Sciences > School of Life Sciences
• Journal Name: British Journal of Nutrition
• Publisher: Cambridge University Press
• ISSN: 0007-1145